A Multicenter Survey of Stage T1 Glottic Cancer Treated with Radiotherapy Delivered in 2.25-Gy Fractions in Clinical Practice: An Initial 5-year Analysis

Overview

Journal Nagoya J Med Sci

Specialty General Medicine

Date 2016 Dec 24

PMID 28008195

Citations 7

Authors

Yoshiyuki Itoh

Seiji Kubota

Mariko Kawamura

Yoshihito Nomoto

Takayuki Murao

Kouji Yamakawa

Shunichi Ishihara

Naoki Hirasawa

Akiko Asano

Shigeo Yanagawa

Shinji Naganawa

Affiliations

Soon will be listed here.

Abstract

The purpose of this study was to evaluate the acute and late toxicity as well as local control (LC) in T1 glottic cancer (GC) patients treated with hypofractionated radiotherapy (RT) in clinical practice. The Tokai Study Group for Therapeutic Radiology and Oncology started RT treatment with a dose of 2.25 Gy for T1 GC in 2011. Ten institutions combined data from 104 patients with T1 squamous cell carcinoma between 2011 and 2015. In total, 104 patients with T1 GC were irradiated with a standard radiation dose of 63 Gy in 28 fractions.The median follow-up duration was 18 (3.7-49.5) months. Acute grade 3 adverse events were observed in 7 patients, with 4 patients (5%) having dermatitis and 3 patients (4%) having mucositis. Late adverse events above grade 3 were not observed. Two patients developed local recurrence. The rates of acute adverse events in the present study were comparable to those in previous studies that have used 2 Gy fractions of RT.

Citing Articles

Clinical Outcomes of Radiotherapy for Stage 1 Glottic Carcinoma: Comparing Accelerated Hyperfractionation and Once-daily Fractionation.

Endo M, Fukuda Y, Okada K, Ogawa K, Nakamura M, Takahashi S In Vivo. 2023; 37(5):2320-2326.

PMID: 37652523 PMC: 10500519. DOI: 10.21873/invivo.13335.

Optimized radiotherapy treatment strategy for early glottic carcinoma.

Ono T, Itoh Y, Ishihara S, Kawamura M, Oie Y, Takase Y Nagoya J Med Sci. 2023; 85(2):241-254.

PMID: 37346844 PMC: 10281837. DOI: 10.18999/nagjms.85.2.241.

Poor local control of ulcerative T1 glottic cancer treated with 2.25-Gy per fraction radiotherapy.

Oie Y, Itoh Y, Kawamura M, Takase Y, Murao T, Ishihara S Nagoya J Med Sci. 2021; 83(4):811-825.

PMID: 34916724 PMC: 8648532. DOI: 10.18999/nagjms.83.4.811.

Proposal for personalized treatment of early glottic cancer with radiation therapy.

Itoh Y, Ono T Nagoya J Med Sci. 2021; 83(4):663-668.

PMID: 34916710 PMC: 8648522. DOI: 10.18999/nagjms.83.4.663.

Prognostic factors in patients with T1 glottic cancer treated with radiotherapy.

Mucha-Malecka A, Chrostowska A, Urbanek K, Malecki K Strahlenther Onkol. 2019; 195(9):792-804.

PMID: 31214734 PMC: 6704086. DOI: 10.1007/s00066-019-01481-2.

References

Hirasawa N, Itoh Y, Naganawa S, Ishihara S, Suzuki K, Koyama K . Multi-institutional analysis of early glottic cancer from 2000 to 2005. Radiat Oncol. 2012; 7:122. PMC: 3488020. DOI: 10.1186/1748-717X-7-122. View

Reddy S, Hong R, Nagda S, Emami B . Effect of tumor bulk on local control and survival of patients with T1 glottic cancer: a 30-year experience. Int J Radiat Oncol Biol Phys. 2007; 69(5):1389-94. DOI: 10.1016/j.ijrobp.2007.05.077. View

Moon S, Cho K, Chung E, Lee C, Lee K, Chai G . A prospective randomized trial comparing hypofractionation with conventional fractionation radiotherapy for T1-2 glottic squamous cell carcinomas: results of a Korean Radiation Oncology Group (KROG-0201) study. Radiother Oncol. 2013; 110(1):98-103. DOI: 10.1016/j.radonc.2013.09.016. View

. [Japanese translation of common terminology criteria for adverse events (CTCAE), and instructions and guidelines]. Int J Clin Oncol. 2005; 9 Suppl 3:1-82. View

Chera B, Amdur R, Morris C, Kirwan J, Mendenhall W . T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys. 2010; 78(2):461-6. DOI: 10.1016/j.ijrobp.2009.08.066. View

Teshima T . Patterns of care study in Japan. Jpn J Clin Oncol. 2005; 35(9):497-506. DOI: 10.1093/jjco/hyi142. View

Jin J, Liao Z, Gao L, Huang X, Xu G . Analysis of prognostic factors for T(1)N(0)M(0) glottic cancer treated with definitive radiotherapy alone: experience of the cancer hospital of Peking Union Medical College and the Chinese Academy Of Medical Sciences. Int J Radiat Oncol Biol Phys. 2002; 54(2):471-8. DOI: 10.1016/s0360-3016(02)02920-6. View

Yamazaki H, Nishiyama K, Tanaka E, Koizumi M, Chatani M . Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time. Int J Radiat Oncol Biol Phys. 2005; 64(1):77-82. DOI: 10.1016/j.ijrobp.2005.06.014. View

Teshima T, Numasaki H, Nishio M, Ikeda H, Sekiguchi K, Kamikonya N . Japanese structure survey of radiation oncology in 2009 based on institutional stratification of the Patterns of Care Study. J Radiat Res. 2012; 53(5):710-21. PMC: 3430417. DOI: 10.1093/jrr/rrs028. View

10.

Izuno I, Sone S, Oguchi M, Kiyono K, Takei K . Treatment of early vocal cord carcinoma with 60Co gamma rays, 8/10 MV x-rays, or 4 MV x-rays--are the results different?. Acta Oncol. 1990; 29(5):637-9. DOI: 10.3109/02841869009090067. View

11.

Tong C, Au K, Ngan R, Chow S, Cheung F, Fu Y . Impact and relationship of anterior commissure and time-dose factor on the local control of T1N0 glottic cancer treated by 6 MV photons. Radiat Oncol. 2011; 6:53. PMC: 3124409. DOI: 10.1186/1748-717X-6-53. View

12.

Laskar S, Baijal G, Murthy V, Chilukuri S, Budrukkar A, Gupta T . Hypofractionated radiotherapy for T1N0M0 glottic cancer: retrospective analysis of two different cohorts of dose-fractionation schedules from a single institution. Clin Oncol (R Coll Radiol). 2012; 24(10):e180-6. DOI: 10.1016/j.clon.2012.07.001. View

13.

Hirasawa N, Itoh Y, Ishihara S, Kubota S, Itoh J, Fujimoto Y . Radiotherapy with or without chemotherapy for patients with T1-T2 glottic carcinoma: retrospective analysis. Head Neck Oncol. 2010; 2:20. PMC: 2919535. DOI: 10.1186/1758-3284-2-20. View

14.

Pfister D, Laurie S, Weinstein G, Mendenhall W, Adelstein D, Ang K . American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol. 2006; 24(22):3693-704. DOI: 10.1200/JCO.2006.07.4559. View

15.

Foote R, Grado G, Buskirk S, Olsen K, Bonner J, Earle J . Radiation therapy for glottic cancer using 6-MV photons. Cancer. 1996; 77(2):381-6. DOI: 10.1002/(SICI)1097-0142(19960115)77:2<381::AID-CNCR22>3.0.CO;2-X. View

16.

Spirydovich S, Papiez L, Moskvin V, DesRosiers P . Evaluation of underdosage in the external photon beam radiotherapy of glottic carcinoma: Monte Carlo study. Radiother Oncol. 2005; 78(2):159-64. DOI: 10.1016/j.radonc.2005.11.010. View

17.

Akine Y, Tokita N, Ogino T, Tsukiyama I, Egawa S, Saikawa M . Radiotherapy of T1 glottic cancer with 6 MeV X rays. Int J Radiat Oncol Biol Phys. 1991; 20(6):1215-8. DOI: 10.1016/0360-3016(91)90230-2. View

18.

Motegi A, Kawashima M, Arahira S, Zenda S, Toshima M, Onozawa M . Accelerated radiotherapy for T1 to T2 glottic cancer. Head Neck. 2014; 37(4):579-84. DOI: 10.1002/hed.23641. View

19.

Mendenhall W, Amdur R, Morris C, Hinerman R . T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. J Clin Oncol. 2001; 19(20):4029-36. DOI: 10.1200/JCO.2001.19.20.4029. View